Plain-English translation of NCT07326813 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called D-2570 to see if it can help people with moderate to severe plaque psoriasis — a skin condition that causes thick, scaly patches. Researchers will compare this medication to both a placebo (a dummy pill with no active ingredient) and an existing psoriasis treatment to understand how well and safely it works.
While there are some treatments available for psoriasis, many patients still struggle to control their symptoms or experience side effects. This trial is testing whether this medication could offer people with moderate to severe psoriasis a new, more effective option.
You likely qualify if…
You likely don't qualify if…
If you join, you will be randomly assigned to receive either the new medication D-2570 at different doses, an existing psoriasis treatment, or a placebo. You'll visit the study site several times for safety checks and skin assessments, and you'll provide blood samples so researchers can measure how the medication works in your body. Neither you nor your doctor will know which treatment you're receiving until the study ends — this helps keep the results fair and unbiased.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
China